Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves Johnson & Johnson’s nasal spray for depression
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
6h
Johnson & Johnson price target lowered to $155 from $170 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.
2d
Chicago Bears hire Ben Johnson as head coach, stealing away Lions offensive coordinator
Ben Johnson, Detroit Lions offensive coordinator, will be hired by Chicago Bears as head coach, adding further intrigue to ...
1d
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
6h
Johnson & Johnson price target lowered to $165 from $170 at Raymond James
Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares.
1d
on MSN
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its ...
23h
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a ...
7h
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Chicago Bears
New York
Detroit Lions
Q4 2024
Dan Campbell
Feedback